| 國立交通大學 |
2014-12-08T15:42:08Z |
GEM: A Gaussian evolutionary method for predicting protein side-chain conformations
|
Yang, JM; Tsai, CH; Hwang, MJ; Tsai, HK; Hwang, JK; Kao, CY |
| 國立臺灣大學 |
2002 |
GEM: A Gaussian evolutionary method for predicting protein side-chain conformations
|
Yang, Jinn-Moon; Tsai, Chi-Hung; Hwang, Ming-Jing; Tsai, Huai-Kuang; Hwang, Jenn-Kang; Kao, Cheng-Yan |
| 國立臺灣海洋大學 |
2002 |
GEM: a Gaussian Evolutionary Method for predicting protein side-chain conformations
|
Jinn-Moon Yang; Chi-Hung Tsai; Ming-Jing Hwang; Huai-Kuang Tsai; Jenn-Kang Hwang; Cheng-Yan Kao |
| 國立交通大學 |
2014-12-08T15:21:02Z |
GemAffinity: A Scoring Function for Predicting Binding Affinity and Virtual Screening
|
Hsu, Kai-Cheng; Chen, Yen-Fu; Yang, Jinn-Moon |
| 國立交通大學 |
2014-12-08T15:22:08Z |
GemAffinity: a scoring function for predicting binding affinity and Virtual Screening
|
Hsu, Kai-Cheng; Chen, Yen-Fu; Yang, Jinn-Moon |
| 中華大學 |
1998 |
GEMCAB：一個對於可測試性設計的性能標桿電路
|
趙智德; Zhao, Zhi De |
| 臺北醫學大學 |
2005 |
Gemcitabine /Carboplatin chemotherapy for Pure Small Cell Carcinoma of Prostate
|
陳冠州; Chen KC; Chiu AW; Chiang HS; Chu JS; Cheng CJ; |
| 國立臺灣大學 |
2002 |
Gemcitabine and Cisplatin in a Multimodality Treatment for Locally Advanced Non-Small Cell Lung Cancer
|
楊志新; 李元麒; 雷德; 許駿; 鄭安理; 陳育民; 陸坤泰; 彭瑞鵬; 楊泮池; YANG, CHIH-HSIN; LEE, YUNG-CHIE; LUI, LOUIS TAK; HSU, CHIUN; CHENG, ANN-LII; CHEN, YU-MING; LUH, KWEN-TAY; PENG, JUI-PENG; YANG, PAN-CHYR |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Perng R.-P.; Chih-Hsin Yang;Tsai C.M;Wang L.S;Lee Y.C;Chang C.J;Lui L.T;Yen S.H;Hsu C;Cheng A.L;Liu M.Y;Chiang S.C;Chen Y.M;Luh K.T;Huang M.H;Yang P.-C;Perng R.-P.; CHIH-HSIN YANG; Tsai C.M; Wang L.S; Lee Y.C; Chang C.J; Lui L.T; Yen S.H; Hsu C; Cheng A.L; Liu M.Y; Chiang S.C; Chen Y.M; Luh K.T; Huang M.H; Yang P.-C |
| 臺大學術典藏 |
2020-04-10T12:51:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Chiun Hsu;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Yang P.-C.;Perng R.-P.; Perng R.-P.; Yang P.-C.; Luh K.T.; Huang M.H.; Chen Y.M.; Chiang S.C.; Liu M.Y.; Cheng A.L.; Chiun Hsu; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Yang C.H. |
| 臺大學術典藏 |
2020-12-02T02:36:06Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Hsu C.;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Pan-Chyr Yang;Perng R.-P.; Yang C.H.; PAN-CHYR YANG |
| 臺大學術典藏 |
2021-05-26T03:35:12Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; Cheng A.L.; Liu M.Y.; Chiang S.C.; Chen Y.M.; KWEN-TAY LUH; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 臺大學術典藏 |
2021-09-01T02:02:28Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; ANN-LII CHENG; Liu M.Y.; Chiang S.C.; Chen Y.M.; Luh K.T.; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 國立臺灣大學 |
2007 |
Gemcitabine and Ifosfamide as a Second-Line Treatment for Cisplatin- Refractory Metastatic Urothelial Carcinoma: A Phase Ii Study
|
林家齊; 徐志宏; 黃昭淵; 耿孝宜; 蔡育傑; 黃國皓; 鄭安理; 蒲永孝; LIN, CHIA-CHI; HSU, CHIH-HUNG; HUANG, CHAO-YUAN; KENG, HSIAO-YI; TSAI, YU-CHIEH; HUANG, KUO-HOW; CHENG, ANN-LII; PU, YEONG-SHIAU |
| 國立臺灣大學 |
2007-04 |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study
|
Lin, Chia-Chi; Chih-Hung; Hsu; Huang, Chao-Yuan; Keng, Hsiao-Yi; Tsai, Yu-Chieh; Huang, Kuo-How; Cheng, Ann-Lii; Pu, Yeong-Shiau |
| 臺大學術典藏 |
2018-09-10T06:13:47Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin, Chia-Chi;Chih-Hung;Hsu;Huang, Chao-Yuan;Keng, Hsiao-Yi;Tsai, Yu-Chieh;Huang, Kuo-How;Cheng, Ann-Lii;Pu, Yeong-Shiau; Lin, C.-C. and Hsu, C.-H. and Huang, C.-Y. and Keng, H.-Y. and Tsai, Y.-C. and Huang, K.-H. and Cheng, A.-L. and Pu, Y.-S.; Lin, Chia-Chi; CHAO-YUAN HUANG; CHIH-HUNG HSU; Chih-Hung; Hsu; KUO-HOW HUANG; YU-CHIEH TSAI; Huang, Chao-Yuan; ANN-LII CHENG; Keng, Hsiao-Yi; Tsai, Yu-Chieh; YEONG-SHIAU PU; Huang, Kuo-How; Cheng, Ann-Lii; Pu, Yeong-Shiau |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Keng H.-Y; Tsai Y.-C; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:54Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; KUO-HOW HUANG; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-03-04T02:36:02Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Yu-Chieh Tsai;Huang K.-H.;Cheng A.-L.;Pu Y.-S.; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; YU-CHIEH TSAI; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-10-14T02:46:15Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; CHAO-YUAN HUANG; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2022-09-15T01:09:54Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 國家衛生研究院 |
2015-10 |
Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy
|
Chang, LS;Yan, WL;Chang, YW;Yeh, YC;Chen, HW;Leng, CH;Liu, SJ |
| 國立臺灣大學 |
2007 |
Gemcitabine Is Preferentially Chemosensitive in Cyclin D1 or Cyclin E over-Expressing Human Gastric Cancer Cells
|
沈盈君; 鄭安理; SHEN, YING-CHUN; CHENG, ANN-LII |
